iTeos Therapeutics, Inc.

NasdaqGM:ITOS 주식 보고서

시가총액: US$297.0m

iTeos Therapeutics 미래 성장

Future 기준 확인 2/6

iTeos Therapeutics (는) 각각 연간 8.5% 및 56.3% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 14.8% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 -33.8% 로 예상됩니다.

주요 정보

8.5%

수익 성장률

14.8%

EPS 성장률

Biotechs 수익 성장28.4%
매출 성장률56.3%
향후 자기자본 수익률-33.8%
애널리스트 커버리지

Low

마지막 업데이트15 Nov 2024

최근 미래 성장 업데이트

iTeos Therapeutics, Inc. (NASDAQ:ITOS) Third-Quarter Results: Here's What Analysts Are Forecasting For Next Year

Nov 15
iTeos Therapeutics, Inc. (NASDAQ:ITOS) Third-Quarter Results: Here's What Analysts Are Forecasting For Next Year

Recent updates

iTeos Therapeutics, Inc. (NASDAQ:ITOS) Third-Quarter Results: Here's What Analysts Are Forecasting For Next Year

Nov 15
iTeos Therapeutics, Inc. (NASDAQ:ITOS) Third-Quarter Results: Here's What Analysts Are Forecasting For Next Year

iTeos Therapeutics: ESMO Data Showing Signs Of A Real Win For TIGIT

Sep 15

Is iTeos Therapeutics (NASDAQ:ITOS) In A Good Position To Deliver On Growth Plans?

Aug 11
Is iTeos Therapeutics (NASDAQ:ITOS) In A Good Position To Deliver On Growth Plans?

iTeos Therapeutics: Rippling Waves Of TIGIT Pessimism

Jul 09

iTeos Therapeutics, Inc. (NASDAQ:ITOS) Looks Inexpensive But Perhaps Not Attractive Enough

Jan 25
iTeos Therapeutics, Inc. (NASDAQ:ITOS) Looks Inexpensive But Perhaps Not Attractive Enough

iTeos: Readouts From TIGIT And Adenosine Pathway Inhibitors Makes This A Must Watch

Jan 10

Industry Analysts Just Upgraded Their iTeos Therapeutics, Inc. (NASDAQ:ITOS) Revenue Forecasts By 16%

May 13
Industry Analysts Just Upgraded Their iTeos Therapeutics, Inc. (NASDAQ:ITOS) Revenue Forecasts By 16%

Investors Give iTeos Therapeutics, Inc. (NASDAQ:ITOS) Shares A 25% Hiding

Mar 21
Investors Give iTeos Therapeutics, Inc. (NASDAQ:ITOS) Shares A 25% Hiding

The Consensus EPS Estimates For iTeos Therapeutics, Inc. (NASDAQ:ITOS) Just Fell Dramatically

Aug 12
The Consensus EPS Estimates For iTeos Therapeutics, Inc. (NASDAQ:ITOS) Just Fell Dramatically

iTeos Therapeutics GAAP EPS of $0.16 misses by $1.04

Aug 10

iTeos Therapeutics: Too Many Unknowns

Jul 27

News Flash: Analysts Just Made A Captivating Upgrade To Their iTeos Therapeutics, Inc. (NASDAQ:ITOS) Forecasts

May 11
News Flash: Analysts Just Made A Captivating Upgrade To Their iTeos Therapeutics, Inc. (NASDAQ:ITOS) Forecasts

Rainbows and Unicorns: iTeos Therapeutics, Inc. (NASDAQ:ITOS) Analysts Just Became A Lot More Optimistic

Nov 25
Rainbows and Unicorns: iTeos Therapeutics, Inc. (NASDAQ:ITOS) Analysts Just Became A Lot More Optimistic

We Think iTeos Therapeutics (NASDAQ:ITOS) Can Afford To Drive Business Growth

Aug 24
We Think iTeos Therapeutics (NASDAQ:ITOS) Can Afford To Drive Business Growth

iTeos Therapeutics: My Calculations Suggest Q3 Earnings Will Exceed $10 Per Share

Aug 15

GlaxoSmithKline - iTeos deal intensifies competition in anti-TIGIT space: Piper Sandler

Jun 15

We Think iTeos Therapeutics (NASDAQ:ITOS) Can Easily Afford To Drive Business Growth

Feb 07
We Think iTeos Therapeutics (NASDAQ:ITOS) Can Easily Afford To Drive Business Growth

Is iTeos Therapeutics, Inc. (NASDAQ:ITOS) Popular Amongst Institutions?

Dec 16
Is iTeos Therapeutics, Inc. (NASDAQ:ITOS) Popular Amongst Institutions?

iTeos Therapeutics EPS misses by $0.11

Nov 12

수익 및 매출 성장 예측

NasdaqGM:ITOS - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜수익수익잉여 현금 흐름작전 현금평균 애널리스트 수
12/31/202628-203-129-1525
12/31/20257-199-110-1365
12/31/202435-135-104-1005
9/30/202435-121-120-117N/A
6/30/202435-108-118-114N/A
3/31/2024N/A-135-113-110N/A
12/31/202313-113-107-104N/A
9/30/202367-62-119-117N/A
6/30/202386-28-114-113N/A
3/31/202312812-115-114N/A
12/31/202226897-112-111N/A
9/30/2022454261-144-143N/A
6/30/2022539330490492N/A
3/31/2022497298503504N/A
12/31/2021345215512513N/A
9/30/202110415565566N/A
6/30/2021N/A-67-49-49N/A
3/31/2021N/A-50-41-40N/A
12/31/2020N/A-43-26-25N/A
9/30/2020N/A-35-27-27N/A
6/30/2020N/A-31-22-22N/A
3/31/2020N/A-28-18-18N/A
12/31/2019N/A-27-24-23N/A

애널리스트 미래 성장 예측

수입 대 저축률: ITOS 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 vs 시장: ITOS 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

고성장 수익: ITOS 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 대 시장: ITOS 의 수익(연간 56.3% ) US 시장( 9% 보다 빠르게 성장할 것으로 예상됩니다. 9% 연간).

고성장 수익: ITOS 의 수익(연간 56.3% )은 연간 20% 보다 빠르게 증가할 것으로 예상됩니다.


주당 순이익 성장 예측


미래 자기자본 수익률

미래 ROE: ITOS (는) 3년 내에 수익성이 없을 것으로 예상됩니다.


성장 기업 발견